DOP60 Vedolizumab treatment persistence and safety in an extended access program (XAP)
ECCO'20 Vienna
2020
DOP62 Morbidity after primary ileocecal resection for Crohn’s disease in the years of biologics: Lesson learned over 631 patients exclusively treated in a tertiary centre
ECCO'20 Vienna
2020
DOP63 Efficacy and safety of iron carboxymaltose on chronic fatigue in patients with inflammatory bowel disease: a randomised controlled trial
ECCO'20 Vienna
2020
DOP64 Discovery of highly selective small-molecule oral inhibitors of integrin α4β7 for the treatment of inflammatory bowel diseases
ECCO'20 Vienna
2020
DOP65 Mirikizumab regulates genes involved in anti-TNF resistance and ulcerative colitis disease activity
ECCO'20 Vienna
2020
DOP66 A CEACAM5 small peptide restores the suppressive activity of CD8 + T cells in patients with Crohn’s disease
ECCO'20 Vienna
2020
DOP67 CKD-506, a selective histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis through regulation of NF-kB and AP-1 signalling pathway
ECCO'20 Vienna
2020
DOP68 Thiomyristoyl ameliorates colitis by blocking the differentiation of Th17 cells via STAT3/IL-6 signal pathway
ECCO'20 Vienna
2020
DOP69 Tofacitinib in ulcerative colitis: Early ‘real-world’ experience from four UK tertiary centres
ECCO'20 Vienna
2020
DOP70 High-dimensional analysis reveals a novel signature for IL-17 producing CD8 T cells in inflammatory bowel disease
ECCO'20 Vienna
2020
DOP71 Efficacy, safety, and tolerability of ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: Results from, UniStar, a phase 1 study
ECCO'20 Vienna
2020
DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study
ECCO'20 Vienna
2020